Abstracts tagged "antibodies and diagnosis"

Abstract Number: 515 • 2013 ACR/ARHP Annual Meeting
Does Multiplex Flow Immunoassay Underdetect SSA and SSB Antibodies? An Evaluation Of The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Alan N. Baer¹, Laura Gutierrez², Mara McAdams DeMarco³, Mi Y. Lam⁴, Livia Casciola-Rosen⁵, Stephen Shiboski⁶, Caroline Shiboski⁴ and Lindsey A. Criswell⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Center Tower Ste 5300, Johns Hopkins University, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶University of California, San Francisco, San Francisco, CA, ⁷Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Multiplex flow immunoassays (MFIA) are used by clinical laboratories to test for antibodies to extractable nuclear antigens. The use of blended Ro52 and…
Abstract Number: 516 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Seronegative Sjogren’s Syndrome: A Comparative Study From The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Alan N. Baer¹, Laura Gutierrez², Mara McAdams DeMarco³, Mi Y. Lam⁴, Livia Casciola-Rosen⁵, Stephen Shiboski⁶, Caroline Shiboski⁴ and Lindsey A. Criswell⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Center Tower Ste 5300, Johns Hopkins University, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶University of California, San Francisco, San Francisco, CA, ⁷Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Individuals with primary Sjogren’s syndrome (SS) may lack systemic autoantibodies. When defined by the absence of anti-SSA and –SSB antibodies, the reported range…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.